Changes in the Immuno-Expression of Galectins -1, -3 and -7 in Relation to the Biological Behavior of Lip Squamous Cell Carcinoma

Maria Manuela R. de Lemos Almeida, Marize Raquel Diniz da Rosa, Pollianna M Alves, Alexandre Rolim da Paz, Marcílio Imbassahy de Almeida Rodrigues, Carlos André Nunes Jatobá


Objective: To evaluate the expression through immunohistochemistry of galectins -1, -3 and -7 in cases of lip squamous cell carcinoma (SCC) in association with clinical data and morphological parameters proposed by Bryne (1998). Material and Methods: Thirty paraffin-embedded SCC cases were submitted to histological sections. Two independent pathologists performed the analysis of galectins -1, -3 and -7 through light microscopy evaluating the presence or absence of marking and intensity. The expressions of these proteins were submitted to statistical analysis (chi-square test, Fisher's exact test and Binomial test for the comparison of proportions). Results: Positive expression of galectins -1 and -3 was observed in 93.3% and 43.3% of cases, respectively. However, there was no statistically significant association between these proteins and the clinical variables used. Galectin-7 immuno-expression was present in all cases evaluated and showed statistical significance between marked cell type (parenchyma cells) and regional metastasis and between marked cell type (parenchyma cells) and histological gradation. Conclusion: Changes in the galectins -1, -3 and -7 expression suggest the participation of these proteins in the regulation of cellular functions and that the immuno-expression of these proteins can act as a marker of the biological behavior of lip squamous cell carcinoma.


Galectins; Carcinoma, Squamous Cell; Immunohistochemistry

Full Text:



Bray F, Ren Js, M E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013; 132(5):1133-45. doi: 10.1002/ijc.27711.

Zini A, Czerninski R, Sgan-Cohen H. Oral cancer over four decades: epidemiology, trends, histology, and survival by anatomical sites. J Oral Pathol Med 2010; 39(4):299-305. doi: 10.1111/j.1600-0714.2009.00845.x.

Instituto Nacional do Câncer (Brasil). Incidência de Câncer no Brasil. Estimativa 2014. [Access on 2 Dec 2015]. Available at:

Leffell DJ. The scientific basis of skin cancer. J Am Acad Dermatol 2000; 42(1): S18-S22.

Lopes PSD, Santos MA. Carcinoma de células escamosas labial em paciente jovem. Rev HCPA 2012, 32(1):82-6.

Chiang W F, Liu Sy, Fang Ly, Lin Cn, Wu Mh, Chen YC et al. Overexpression of galectin-1 at the tumor invasion front is associated with poor prognosis in early-stage oral squamous cell carcinoma. Oral Oncology 2008, 44(4):325-34. doi: 10.1016/j.oraloncology.2007.03.004.

Thijssen Vl, Heusschen R, Caers J, Griffioen AW. Galectin expression in cancer diagnosis and prognosis: A systematic review. Biochim Biophys Acta 2015; 1855(2):235-47. doi: 10.1016/j.bbcan.2015.03.003.

Alves PM, Godoy GP, Gomes DQ, Medeiros AMC, Souza LB, Silveira EJD. Significance of galectins-1, -3, -4 and -7 in the progression of squamous cell carcinoma of the tongue. Pathol Res Pract 2011; 207(4):236-40. doi: 10.1016/j.prp.2011.02.004.

Kohrenhagen N, Volker HU, Kapp M, Dietil J, Kammerer U. Increased expression of galectin-1 during the progression of cervical neoplasia. Int J Gynecol Cancer 2006; 16(6):2018-22.

Saussez S, Decaestecker C, Lorfevre F, Chevallier D, Mortuaire G, Kaltner H et al. Increased expression and altered intracellular distribution of adhesion/growth-regulatory lectins galectins-1 and -7 during tumor progression in hypopharyngeal and laryngeal squamous cell carcinomas. Histopathology 2008; 52(4):483-93. doi: 10.1111/j.1365-2559.2008.02973.x.

Davidson PJ, Davis MJ, Patterson RJ, Ripoche MA, Poirier F, Wang JL. Shuttling of galectin -3 between the nucleus and cytoplasm. Glycobiology 2002; 12(5):329-37.

Fukumori T, Kanayama H, RAZ A. The role of galectin -3 in câncer drug resistance. Drug Resist Updat 2007; 10(3):101-8. doi: 10.1016/j.drup.2007.04.001.

Chovanec M, Smetana K, Plzák J, Betka J, Plzakova Z, Stork J et al. Detection of new diagnostic markers in pathology by focus on growth-regulatory endogenous lectins. The case study of galectin-7 in squamous epithelia. Prague Med Rep 2005; 106(2):209-16.

Carvalho MV, Pereira JS, Alves PM, Silveira EJD, Souza LB, Queiroz LMG. Alterations in the immunoexpression of galectins -1, -3 e -7 between different grades of oral epithelial dysplasia. J Oral Pathol Med 2013; 42(2):174-9. doi: 10.1111/j.1600-0714.2012.01199.x.

Honjo Y, Inohara H, Akahanis S, Yoshi T, Takenaka Y, Yoshida J et al. Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res 2000; 6(12):4635-40.

Chawla S, Warren TA, Wockner LF, Lambie DLJ, Brown IS et al. Galectin -1 is associated with poor prognosis in patients with cutaneous head and neck cancer with perineural spread. Cancer Immunol Immunother 2016; 65(2):213-22. doi: 10.1007/s00262-015-1788-z.

Bryne M. Is the invasive front of an oral carcinoma the most important area for prognostication? Oral diseases 1998; 4(2):70-7.

Kim HJ, Do IG, Jeon HK, Cho YJ, Park YA, Choi JJ, Sung CO et al. Galectin 1 expression is associated with tumor invasion and metastasis in stage IB to IIA cervical cancer. Hum Pathol 2013; 44(1):62-8. doi: 10.1016/j.humpath.2012.04.010.

Sheehan GM, Kallakury BVS, Sheehan CE, Fisher HAG, Kaufman Jr RP, Jeffrey SR. Loss of claudins-1 and -7 and expression of claudins -3 and -4 correlate with prognostic variables in prostatic adenocarcinomas. Hum Pathol 2007; 38(4):564-9.

Schaaij-Visser TB, De Wit M, Lam SW, Jimenez CR. The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context.. Biochim Biophys Acta 2013; 1834(11): 2242-58. doi: 10.1016/j.bbapap.2013.01.029.

Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Neuzillet C, Albert S, et al. Unraveling galectin -1 as a novel therapeutic target for câncer. Cancer Treat Rev 2014; 40(2):307-19. doi: 10.1016/j.ctrv.2013.07.007.

Wu H, Chen P, Liao R, Li YW, Yi Y, Wang JX et al. Overexpression of galectin -1 is associated with poor prognosis in human hepatocellular carcinoma following resection. J Gastroenterol Hepatol 2012; 27(8):1312-9. doi: 10.1111/j.1440-1746.2012.07130.x.

Jung EJ, Moon HG, Cho BI, Jeong CY, Joo YT, Lee YJ et al. Galectin-1 expression in cancer associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int J Cancer 2007; 120(11):2331-8.

Krzeslak A, Lipinska A. Galectin-3 as a multifunctional protein. Cell Mol Biol Lett 2004; 9(2):305-28.

Lee JW, Song SY, Choi JJ, Choi CH, Kim TJ, Kim J et al. Decreased galecin-3 expression during the progression of cervical neoplasia. J Cancer Res Clin Oncol 2006; 132(4):241-7. doi:10.1007/s00432-005-0069-1.

Saussez S, Kiss R. Galectin -7. Cell Mol Life Sci 2006; 63:686-697.

Saussez S, Decaestecker C, Lorfevre F, Chevallier D, Mortuaire G, Kaltner H et al. Increased expression and altered intracellular distribution of adhesion/growth-regulatory lectins galectins-1 and -7 during tumor progression in hypopharyngeal and laryngeal squamous cell carcinomas. Histopathology 2008; 52(4):483-93. doi: 10.1111/j.1365-2559.2008.02973.x.

Matsukawa S, Morita K, Negishi A, Harada H, Nakajima Y, Shimamoto H, et al. Galectin -7 as a potential predictive marker of chemo-and/or radio-therapy resistance in oral squamous cell carcinoma. Cancer Med 2014; 3(2):349-61. doi: 10.1002/cam4.195.

Yamaguchi T, Hiromasa K, Kabashima-Kubo R, Yoshioka M, Nakamura M. Galectin -7, induced by cis-urocanic acid and ultraviolet B irradiation, down-modulates cytokine production by T lymphocytes. Exp Dermatol 2013; 22(12):832-49. doi: 10.1111/exd.12268.

Kim SJ,Hwang JA, Ro JY, Lee YS, Chun KH. Galectin -7 is epigenetically-regulated tumor suppressor in gastric cancer. Oncotarget 2013; 4(9):1461-71. doi: 10.18632/oncotarget.1219.


PBOCI is a member of CrossRef and all the content of its journals are linked by DOIs through CrossRef.